Between 2007 and 2015, a total of 346 patients underwent RARC at multiple tertiary referral centers in Korea. Median follow-up was 33 months (interquartile range [IQR]: 7—50). The number of patients with organ-confined and lymph node (LN)-positive disease were 237 (68.4%) and 68 (19.7%), respectively. LN density (1-20 versus > 20) was 13.6% and 6.1%, with a median of 17 nodes removed (IQR: 9-23). In logistic regression analysis, type of LN dissection and pathologic tumor stage were significant predictors of cancer recurrence and cancer death. Local and distant recurrence and secondary UC occurred in 7 (2.0%), 53 (15.3%), and 4 (1.2%) patients, respectively. The 5-year overall survival, cancer-specific survival, and recurrence-free survival (RFS) were 78%, 84%, and 73%, respectively. At last follow-up, RFS for extended pelvic LN dissection versus standard pelvic LN dissection was 70% and 47% (P= 0.038).
The authors concluded that patients undergoing RARC at their centers demonstrated intermediate-term oncologic outcomes, predictive factors for recurrence, and recurrence patterns that were similar to previous studies.
Presented by: Shim Js
Affiliation: Seoul, South Korea; Kyungpook National University School of Medicine, Daegu, South Korea
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal